<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272531</url>
  </required_header>
  <id_info>
    <org_study_id>NIH 1 U01 MH92758-01</org_study_id>
    <nct_id>NCT01272531</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)</brief_title>
  <official_title>Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this
      work is to identify genes associated with good response of patients with bipolar disorder to
      two commonly used mood stabilizing agents, lithium and valproate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects meeting study inclusion criteria will be started on lithium. Those that fail
      lithium will be crossed over to valproate (VPA). Those that also fail VPA will be again
      crossed-over to a standardized treatment as usual (TAU) arm. Subjects who are eligible for
      the study must be at least 18 years of age and have been diagnosed or are thought to have
      bipolar I disorder with at least one episode of mood instability in the last 12 months. They
      must also be eligible to take lithium and, if female and of child bearing age, agree to use
      adequate birth control methods and to inform their doctor of their plans to become pregnant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>every 2 months for 2 years</time_frame>
    <description>Relapse definition:
meets criteria for mania and is considered &quot;markedly ill&quot; or worse; or
meets criteria for major depression with 4 week duration;
meets criteria for a mixed episode and is considered &quot;markedly ill&quot; or worse.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Bipolar Affective Disorder</condition>
  <arm_group>
    <arm_group_label>lithium</arm_group_label>
    <description>All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valproate</arm_group_label>
    <description>Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mood stabilizer treatment</intervention_name>
    <description>lithium or valproate</description>
    <arm_group_label>lithium</arm_group_label>
    <arm_group_label>valproate</arm_group_label>
    <other_name>lithium carbonate</other_name>
    <other_name>Eskalith</other_name>
    <other_name>Lithobid</other_name>
    <other_name>divalproex sodium</other_name>
    <other_name>Depakote</other_name>
    <other_name>Depakene</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from patients with bipolar disorder
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatient and outpatients with bipolar affective disorder
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any phase of bipolar I disorder including, depressive, manic, hypomanic, mixed, or
             baseline/euthymic/not symptomatic;

          -  Lithium na√Øve patients and inadequately past lithium treated patients will be required
             to have had at least one affective episode in the last 12 months meeting DSM-IV
             criteria. Current lithium treated patients (CLTPs) will be stable on lithium
             monotherapy and will be exempted from this criterion if they have had no mood episodes
             meeting DSM-IV criteria in the last 6 months;

          -  Both outpatients and inpatients will be permitted to enroll into this study;

          -  Able to give informed consent, in the judgment of the investigator;

          -  Age greater than or equal to 18 years;

          -  Women of child bearing potential agree to inform their doctor at the earliest possible
             time of their plans to conceive, and to use adequate contraception (e.g. oral
             contraceptives, intrauterine device, barrier methods, or total abstinence from
             intercourse), and to understand the risks of lithium to the fetus and infant. Depo
             Provera is acceptable if it is started 3 months prior to enrollment.

        Exclusion Criteria:

          -  Unwilling or unable to comply with study requirements;

          -  Renal impairment (serum creatinine &gt;1.5 mg/dL);

          -  Thyroid stimulating hormone (TSH) over &gt;20% above the upper normal limit (participants
             maintained on thyroid medication must be euthyroid for at least 3 months before Visit
             1;

          -  Other contraindication to lithium;

          -  Currently in crisis such that inpatient hospitalization or other crisis management
             should take priority;

          -  Subjects with alcohol/drug dependence who meet criteria for physical dependence
             requiring acute detoxification;

          -  Pregnant or breastfeeding;

          -  Women of child-bearing potential who aren't able to agree to the requirements
             specified above;

          -  Those who have participated in a clinical trial of an investigational drug within the
             past 1 month;

          -  Inability to agree to comply with the visit schedule or study procedures;

          -  History of lithium toxicity, not due to mismanagement or overdose that required
             treatment;

          -  Current unstable medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Kelsoe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna DeModena</last_name>
    <phone>858-642-3590</phone>
    <email>ademodena@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan G Leckband, R.Ph.</last_name>
    <phone>858-552-8585</phone>
    <phone_ext>5337</phone_ext>
    <email>susan.leckband@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna DeModena</last_name>
      <phone>858-642-3590</phone>
      <email>ademodena@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>John R. Kelsoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Romanos</last_name>
      <phone>773-834-5128</phone>
      <email>bromanos@yoda.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Elliot Gershon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Fisher, RN</last_name>
      <phone>317-274-8844</phone>
      <email>cfisher2@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>John Nurnberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce H Tarwater, MSW, LISW</last_name>
      <phone>319-353-5684</phone>
      <email>bruce-tarwater@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>William Coryell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma K Stokes, MHS</last_name>
      <phone>410-550-1652</phone>
      <email>estokes9@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Zandi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Harrington</last_name>
      <phone>877-864-3637</phone>
      <email>BPResearch@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Melvin McInnis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Conroy</last_name>
      <phone>216-844-2871</phone>
      <email>Carla.Conroy@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Joe Calabrese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Guy-Frank</last_name>
      <phone>215-746-6414</phone>
      <email>guyfrank@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Wade Berrettini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Garnham, RN BN</last_name>
      <phone>(902) 473-7144</phone>
      <email>jgarnham@dal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Claire Slaney</last_name>
      <phone>(902) 473-5884</phone>
      <email>Claire.Slaney@cdha.nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Alda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5020</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Jakobsen</last_name>
      <phone>(+47) 55 95 84 67</phone>
      <email>, petter.jakobsen@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Ketil J Oedegaard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lithium.ucsd.edu</url>
    <description>PGBD website</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>John R. Kelsoe, MD</name_title>
    <organization>University of California, San Diego</organization>
  </responsible_party>
  <keyword>pharmacogenetics</keyword>
  <keyword>bipolar disorders</keyword>
  <keyword>affective disorders</keyword>
  <keyword>mood disorders</keyword>
  <keyword>pharmacologic actions</keyword>
  <keyword>psychotropic drugs</keyword>
  <keyword>antimanic agents</keyword>
  <keyword>antidepressant agents</keyword>
  <keyword>lithium</keyword>
  <keyword>lithium carbonate</keyword>
  <keyword>Lithobid</keyword>
  <keyword>Eskalith</keyword>
  <keyword>divalproex</keyword>
  <keyword>divalproex sodium</keyword>
  <keyword>Depakote</keyword>
  <keyword>valproate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

